Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Kadant will release Q2 2026 results after market close Aug 4 and host an earnings webcast and call Aug 5.
  • CN is supporting more than 300 customer growth projects across its North American rail network.
  • CN plans to bring 30 projects into service in 2026 and has 70 more planned.
  • CN has invested about $2.8 billion this year in capital improvements to enhance network capacity and resilience.
  • CN projects underpin major infrastructure such as LNG Canada and BC Hydro Site C.
  • First Western rang the Nasdaq closing bell to mark 25 years and said assets have roughly tripled since its IPO.

Latest Articles

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
May 14, 2026
Leila Farooq
Press Releases

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

EyePoint, Inc. announced the independent Data Safety Monitoring Committee (DSMC) has completed its third positive review of the Phase 3 trials for DURAVYUTM, a sustained-release intravitreal treatment for wet age-related macular degeneration (wet AMD). The DSMC recommends continuation of the ongoing LUGANO and LUCIA trials without modifications, ba…

EYPT
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
Caleb Monroe
Press Releases

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CAMP4 Therapeutics announced new preclinical data showing that their lead candidate, CMP-002, significantly improves seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. These results extend previous evidence of neurodevelopmental benefits and support the planned initiation of a Phase 1/2 clinical trial in SYNGAP1-related diso…

CAMP
XORTX Announces US$5 Million Public Offering
May 14, 2026
Avery Klein
Press Releases

XORTX Announces US$5 Million Public Offering

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company developing treatments for gout and kidney diseases, announced a $5 million public offering of common shares and pre-funded warrants priced at $1.88 per share. The offering is subject to customary regulatory approvals and is intended to support the advancement of their clinical pi…

XRTX
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
May 14, 2026
Derek Hwang
Press Releases

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on CNS disorders, will release its Q1 2026 financial results on May 18, 2026, followed by a conference call. The company is developing therapeutics targeting suicidal depression and related conditions with drug candidates NRX-100 and NRX-101, which have received Fast Track and …

NRXP
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
May 14, 2026
Priya Menon
Press Releases

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective analysis of U.S. real-world claims data on fibromyalgia patients. This follows the August 2025 FDA approval and November 2025 U.S. commercial launch of TONMYA® (cyclobenzaprine HCl sublingual tablets), the first new fibromyalgia treatment in over 15 years.…

TNXP
Concorde International Group Secures Multi-Year Contracts Worth Over US$10 Million for Integrated Security Solutions in Singapore
May 14, 2026
Jordan Park
Press Releases

Concorde International Group Secures Multi-Year Contracts Worth Over US$10 Million for Integrated Security Solutions in Singapore

Concorde International Group Ltd., a technology-enabled security solutions provider, announced it has secured multi-year contracts worth over US$10 million to deliver integrated security solutions across industrial zones, business districts, and community precincts in Singapore. The contracts involve deployment of the company's proprietary i-Guardi…

YOOV
Barrick Announces Election of Directors
May 14, 2026
Caleb Monroe
Press Releases

Barrick Announces Election of Directors

Barrick Mining Corporation announced the election of its board of directors, appointment of auditors, and approval of executive compensation at its 2026 Annual Meeting. The company confirmed strong shareholder support for its governance proposals, reinforcing stable management and oversight as it continues operations across 17 countries.

B
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Leila Farooq
Press Releases

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Tiziana Life Sciences announced initial Phase 2 clinical trial results revealing that intranasal foralumab significantly reduces brain inflammation in patients with Multiple System Atrophy (MSA), as measured by PET imaging. This represents the third neurological condition showing marked inflammation reduction with the therapy, which previously show…

TLSA
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
May 14, 2026
Caleb Monroe
Press Releases

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio, Inc., a clinical-stage biotech company, announced it will present new clinical data for its investigational drug budoprutug at the European Hematology Association 2026 Congress. The data includes safety and efficacy results from a Phase 1b/2a trial in patients with primary immune thrombocytopenia, highlighting budoprutug’s potential as a…

CLYM
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
May 14, 2026
Jordan Park
Press Releases

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio presented encouraging clinical and translational data for its autologous CAR T cell therapy rese-cel at the ASGCT 2026 Annual Meeting. The data showed that the lowest dose of preconditioning-free rese-cel produced compelling drug-free responses in half of treated refractory patients with pemphigus vulgaris over six months. Additionall…

CABA
Yardeni: Fed Rate Cut in 2026 Now Unlikely as Inflation and Labor Strengthen
May 14, 2026
Avery Klein
Economy

Yardeni: Fed Rate Cut in 2026 Now Unlikely as Inflation and Labor Strengthen

Yardeni Research says the Federal Reserve's tilt toward easing is becoming harder to justify and may soon be replaced by a tightening orientation. The firm argues a 2026 rate cut is "essentially off the table," citing renewed inflation momentum, five consecutive years above the Fed's 2% goal, inflationary pressures from AI infrastructure investment…